Table 2.

Fed serum glucose (mg/dL) of the experimental groups on days 1, 3 and 6 of the study.

Day	Group
	CON-NS	CON-LL	CON-LH	DEX-NS	DEX-LL	DEX-LH
1	110.5 ± 5.73	107.3 ± 0.76	115.5 ± 1.47	120.1 ± 5.06	104.8 ± 4.07	114.7 ± 4.78
3	109.8 ± 5.26	103.5 ± 1.16	129.6 ± 1.28	215.6 ± 29.08 a,b	196.5 ± 17.27 a,b	178.1 ± 15.18 a,b
6	109.8 ± 5.26	110.0 ± 1.64	130.7 ± 2.25	267.3 ± 31.51 a,b	255.2 ± 23.44 a,b	215.6 ± 22.33 a,b

Values are expressed as mean ± SE. Control non-supplemented group (CON-NS; n = 10); Control leucine supplemented group with low dose via gavage (CON-LL; n = 10); Control leucine supplemented group with high dose via gavage (CON-LH; n = 10); DEXA non supplemented group (DEX-NS; n = 10); DEXA treated group plus low dose of leucine supplementation via gavage (DEX-LL; n = 10); DEXA treated group plus high dose of leucine supplementation via gavage (DEX-LH; n = 10). ^a p < 0.05 vs. CON-NS in the same day of treatment; ^b p < 0.05 vs. day 1 in the same group.